Skip to content

OnyxBiotech News

Subscribe About Onyx
Cell & Gene Leaders Live Sunday 15 November 2026 · The Shard (Shangri-La), London · One-day summit for cell & gene therapy leaders Sunday 15 November 2026 · The Shard (Shangri-La), London Get tickets → London Life Sciences Week Guide The unofficial London Life Sciences Week Guide, published by Onyx Newsroom · Every event 15–19 November 2026 Every event 15–19 November 2026 · Published by Onyx Newsroom Plan your week →
FDA Greenlit

FDA approves AstraZeneca's Baxfendy, an aldosterone synthase inhibitor for uncontrolled hypertension

Baxdrostat lowered systolic pressure by a placebo-adjusted 9.8 mmHg in patients already taking at least two antihypertensives including a diuretic, targeting the aldosterone pathway behind much of resistant hypertension.

A blood pressure cuff and gauge on a patient's arm
Table of Contents

The FDA on May 15, 2026 approved Baxfendy (baxdrostat), AstraZeneca's once-daily tablet, in combination with other antihypertensive drugs for adults whose hypertension is not adequately controlled on other agents.

Baxdrostat inhibits aldosterone synthase, the enzyme that produces aldosterone in the adrenal gland. Excess aldosterone raises blood volume through renal sodium and water retention and contributes to vascular inflammation and fibrosis. Mineralocorticoid receptor antagonists such as spironolactone address the receptor downstream, constrained by hyperkalemia and, for spironolactone, antiandrogenic effects; baxdrostat stops the hormone being made at all.

BaxHTN (NCT06034743) randomized 794 patients equally to baxdrostat 1 mg, 2 mg or placebo after a two-week placebo run-in. Every patient was on a diuretic, 90% on an ACE inhibitor or ARB, and roughly 41% were taking three background antihypertensives, with mean baseline pressure of 149/87 mmHg. At Week 12 systolic pressure fell 15.7 mmHg on 2 mg and 14.5 mmHg on 1 mg against 5.8 mmHg on placebo, placebo-adjusted reductions of 9.8 and 8.7 mmHg. In an eight-week randomized withdrawal the effect held, separating from placebo by 5.1 mmHg.

Potassium monitoring is the predictable consequence of suppressing aldosterone, and will determine how comfortably this sits in primary care.

Clinically, it adds a mechanism upstream of the mineralocorticoid receptor antagonists for patients already taking several agents, in the labeled population.


Sources: FDA prescribing information; Drugs@FDA, NDA 219878; AstraZeneca press release; BaxHTN (NCT06034743); Nature Reviews Drug Discovery

Coming up: Cell & Gene Leaders Live, Sun 15 Nov at The Shard · London Life Sciences Week Guide, 15–19 Nov 2026 ·

Comments